SAMSCA (tolvaptan)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age and older

Diagnosis

Patient must have the following:

Euvolemic or hypervolemic hyponatremia

AND the following:

 Medication <u>HAS</u> or <u>WILL BE</u> initiated in the hospital where serum sodium can be monitored closely

AND NONE of the following:

- Used for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
- 2. Used for hypovolemic hyponatremia
- 3. Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms
- 4. Significant liver disease (including cirrhosis)
- 5. Anuria
- 6. Dual therapy with Jynarque (tolvaptan)

Prior - Approval Limits

Quantity

Strength	Quantity
15 mg	120 tablets per 30 days
30 mg	

Duration 1 month (30 days)

Prior – Approval Renewal Requirements

Age 18 years of age and older

Diagnosis



SAMSCA (tolvaptan)

Patient must have the following:

Euvolemic or hypervolemic hyponatremia

AND ALL of the following:

- 1. Medication <u>HAS</u> or <u>WILL BE</u> initiated in the hospital where serum sodium can be monitored closely
- 2. There has been at least a 30 day lapse between the last course of therapy and this course of therapy

AND NONE of the following:

- Used for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
- 2. Used for hypovolemic hyponatremia
- 3. Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms
- 4. Significant liver disease (including cirrhosis)
- 5. Anuria
- 6. Dual therapy with Jynarque (tolvaptan)

Prior - Approval Renewal Limits

Same as above